LOX-24350: a FGFR3 antagonists Drug, Initially developed by Loxo Oncology, Inc., Now, its global highest R&D status is Phase 1, Mechanism: FGFR3 antagonists(Fibroblast growth factor receptor 3 antagonists), Therapeutic Areas: Neoplasms,Urogenital Disease